← Back to Search

MEK Inhibitor

Phase 2 for Neurofibromatosis (Mirda Trial)

Phase 1 & 2

Recruiting

Led By Carlos Romo, MD

Research Sponsored by Johns Hopkins University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Have a minimum of 24 measurable cNF with 2 target areas of at least 6 measurable cNF each

Be at least 18 years of age

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 28 days

Awards & highlights

Mirda Trial Summary

This trial is testing the drug mirdametinib in adults with NF1 and cNF. Participants will go through three phases: screening, treatment, and a follow-up period for safety.

Who is the study for?

Adults over 18 with Neurofibromatosis type 1 (NF1) and at least 12 measurable cutaneous neurofibromas (cNF). They must have a certain level of overall health, including specific blood cell counts and performance status. Participants need to be able to undergo tumor biopsies.Check my eligibility

What is being tested?

The trial is testing Mirdametinib as a single-agent therapy for adults with NF1 and cNF. It's an open-label study, meaning both doctors and patients know what treatment is being given, conducted in multiple doses across three phases: screening, treatment, and follow-up.See study design

What are the potential side effects?

While the side effects are not explicitly listed here, common ones associated with similar medications may include skin reactions at the site of neurofibroma treatment, gastrointestinal issues like nausea or diarrhea, fatigue, liver enzyme changes, rash or other skin changes.

Mirda Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have at least 24 measurable skin growths, with 2 areas having at least 6 each.

Select...

I am 18 years old or older.

Select...

My eligible neurofibromas are in the study's specified areas or can be biopsied if outside those areas.

Select...

I can carry out normal activities with minimal symptoms.

Select...

I agree to follow the specified contraception guidelines.

Select...

My organ and bone marrow functions are within normal ranges.

Mirda Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 28 days

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 28 days

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 28 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Assess the safety of continuous and three week on-one week off dosing of mirdametinib in adults with NF1 and cutaneous neurofibromas (cNFs).

Define the recommended phase 2 dose (RP2D) of mirdametinib in adults with NF1 and cNF.

• Evaluate the preliminary anti-tumor activity of mirdametinib monotherapy in adults with NF1 and cNFs.

Mirda Trial Design

2Treatment groups

Experimental Treatment

Group I: Phase 2Experimental Treatment1 Intervention

For the Phase 2 portion, treatment will be administered based on recommended RP2D from Phase 1. All participants will receive study drug until: cessation of study treatment due to death, intolerance, or withdrawal of consent from the study; completion of 24 cycles of treatment (unless the investigator's benefit-risk assessment supports continued treatment; disease progression; or Investigator's decision. Treatment period ends with the administration of the last dose. The study ends 30 days after the last dose.

Group II: Phase 1Experimental Treatment1 Intervention

For the Phase 1 portion, treatment will be administered continuously (Dose regimens 1, 2, 4) or intermittently (Dose regimen 3; 3 weeks on/1 week off) in 28-day cycles). All participants will receive study drug until: cessation of study treatment due to death, intolerance, or withdrawal of consent from the study; completion of 24 cycles of treatment (unless the investigator's benefit-risk assessment supports continued treatment); participants enroll in the phase 2a portion of the study; disease progression; or Investigator's decision. Treatment period ends with the administration of the last dose. The study ends 30 days after the last dose

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Mirdametinib

2021

Completed Phase 2

~10

0 / 6Eligibility criteria met

Find a Location

Who is running the clinical trial?

Johns Hopkins UniversityLead Sponsor

2,266 Previous Clinical Trials

14,837,473 Total Patients Enrolled

Neurofibromatosis Therapeutic Acceleration ProgramUNKNOWN

1 Previous Clinical Trials

500 Total Patients Enrolled

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsLead Sponsor

558 Previous Clinical Trials

32,896 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are individuals currently eligible to participate in this ongoing clinical trial?

"Per details on clinicaltrials.gov, this study is actively enrolling participants. The trial was first listed on February 12th, 2024 and most recently revised on February 27th, 2024."

Answered by AI

What is the current participation count in this clinical trial?

"Yes, the information on clinicaltrials.gov highlights that this clinical trial is currently seeking participants. Initially shared on February 12th, 2024, and last updated on February 27th, 2024, the study aims to enroll a total of 24 patients from one designated site."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).

2024. "Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06159166.

All > Nf 1 > Neurofibromatosis